Saints&Sages Announces Completion of ￥100 Million Series A Funding Round

(VCBeat) Mar. 9, 2021 -- Shanghai Shengzhe Medical Technology Co., Ltd. ("Saints&Sages"), which focuses on the development of minimally invasive surgical instruments, has successfully closed on a ￥100 million Series A financing, led by Qiming Venture Partners, with participation from TF Capital and several existing shareholders.

Saints&Sages plans to use the funds to accelerate the development of its products and market expansion.

Founded in December 2017 in Shanghai Zhangjiang Science City, Saints&Sages' core team consists of Drs, managers and senior engineers of well-known multinational enterprises and elites of the domestic medical industry. Sz medical is committed to developing innovative surgical products.

Saints&Sages provides minimally invasive surgery (MIS) solutions in gastrointestinal surgery, hepatobiliary surgery, gynecology, urology, glandular surgery, thoracic surgery, and other departments. At present, Saints&Sages has built an R&D pipeline of energy surgical devices, including the SanAgile ultrasonic cutting hemostatic knife system, SanPulse UHF integrated surgical system and SapPare laparoscopic stapler. Among them, the first generation of SanAgile, which is in the most rapid development, has been approved for registration, and the second generation has passed type testing and animal testing.

Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Shenzhen, Hong Kong, Seattle, Boston, and San Francisco Bay Area. Currently, Qiming Venture Partners manages seven US Dollar funds and five RMB funds with over US$4 billion assets under management. Qiming Venture Partners invests in information technology, new consumer business patterns, and the healthcare sector.

TF Capital focuses on investment in the life sciences industry, primarily investing in early-stage companies with high potential.  Through strategic investments in various key areas (including biotechnology, therapeutics & pharmaceuticals, drug delivery, medical device & instruments, medical services) and right partnerships, TF Capital hopes to capture opportunities in the rapidly expanding Chinese life sciences market.